Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
The presentation will be webcast live and may be accessed by visitingAmicus' website at www.amicustherapeutics.com. A replay of the webcast willalso be available on the Company's website until February 25, 2008.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oraltherapeutics known as pharmacological chaperones for the treatment of a rangeof human genetic diseases. Pharmacological chaperone technology involves theuse of small molecules that selectively bind to and stabilize proteins incells, leading to improved protein folding and trafficking, and increasedactivity. Amicus is initially targeting lysosomal storage disorders, which aresevere, chronic genetic diseases with unmet medical needs. Amicus hascompleted Phase 2 clinical trials of Amigal for the treatment of Fabry diseaseand is conducting Phase 2 clinical trials of Plicera(TM) for the treatment ofGaucher disease. The Company has completed Phase 1 clinical trials of AT2220for the treatment of Pompe disease.
Amicus cautions you that statements included in this press release thatare not a description of historical facts are "forward-looking statements"within the meaning of Section 21E of the Private Securities Litigation ReformAct of 1995. Words such as, but not limited to, "look forward to," "believe,""expect," "anticipate," "estimate," "intend," "plan," "targets," "likely,""will," "would," "should," and "could," and similar expressions or wordsidentify forward-looking statements. Such forward-looking statements are basedupon current expectations that involve risks, changes in circumstances,assumptions and uncertainties. The inclusion of forward-looking statementsshould not be regarded as a representation by Amicus that any of its planswill be achieved. Any or all of the forward-looking statements in this pressrelease may turn out to be wrong. They can be affected by inaccurateassumptions Amicus might make or by known or unknown risks and uncertainties.For example, with respect to statements regarding the potential progress andresults of clinical trials, actual results may differ materially from thoseset forth in this release due to the risks and uncertainties inherent in thebusiness of Amicus, including, without limitation: the effect of thecompletion of the Phase 2 clinical trial for Amigal(TM) for the treatment ofFabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase2 clinical trials for Plicera(TM) for the treatment of Gaucher disease, andthe effect of the completion of the Phase 1 clinical trials for AT2220 for thetreatment of Pompe disease may not proceed in the timeframes or in the mannerAmicus expects or at all. Further, the results of earlier clinical trials maynot be predictive of future results; Amicus and its licensors may not be ableto obtain, maintain and successfully enforce adequate patent and otherintellectual property protection of its product candidates; and other risksdetailed in the public filings of Amicus with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionarystatement and Amicus undertakes no obligation to revise or update this newsrelease to reflect events or circumstances after the date hereof. This cautionis made under the safe harbor provisions of Section 21E of the PrivateSecurities Litigation Reform Act of 1995.
You May Also Like